Extraordinary General Meeting 2018

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden, Wednesday 5 December 2018 at 3:00 p.m. Coffee will be served starting at 2:00 p.m., at which time the registration for attendees will commence.

Right to participate and notice

Shareholders who wish to participate at the Extraordinary General Meeting must be entered in the share register of the Company, kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation), on Thursday 29 November 2018 and must notify their intention to participate to the Company so that the notification is received by the Company no later than on Thursday 29 November 2018. Shareholders may bring one or two assistants at the Extraordinary General Meeting if notification of the number of assistants that the shareholder intends to bring has been made to the Company no later than by the aforementioned time.

The notification shall be made in writing to Oncopeptides AB (publ), Luntmakargatan 46, 111 37 Stockholm, Sweden, or by e-mail to adrienne.martin-lof@oncopeptides.com. The notification shall include name, personal identification number or corporate registration number, number of shares, address and daytime telephone number and, where applicable, name of assistant, proxy or representative. A notification form is available on the Company’s website, www.oncopeptides.com.

Nominee registered shares

In order to be entitled to participate at the Extraordinary General Meeting, shareholders who have their shares registered in the name of a nominee must temporarily re-register the shares in their own name. Shareholders who wish to make such re-registration, so-called voting rights registration, must make such request with their nominee well in advance of Thursday 29 November 2018, at which time the re-registration must have been made.

Proxy

Shareholders intending to participate by proxy must issue a written, signed and dated power of attorney. If the power of attorney is issued by a legal entity, the power of attorney shall be accompanied by a certified copy of a valid registration certificate of the legal entity (or similar document for a non-Swedish legal entity). The documents must not be older than one year, however the power of attorney may be older in case its wording provides for longer validity, however maximum five years. A power of attorney form is available on the Company’s website, www.oncopeptides.com, and will be sent free of charge to shareholders who so request and provide their postal or e-mail address. In order to facilitate registration, original versions of powers of attorney, certificates of registration and other authorization documents should be sent to the Company at the above address well in advance of the Extraordinary General Meeting.

Documents

The full proposed resolution according to item 10 and information regarding the proposed member of the Board of Directors will be made available at the Company’s website, www.oncopeptides.com, no later than Wednesday 14 November 2018 and at the premises of the Company, address Luntmakargatan 46, 111 37 Stockholm, Sweden, and will be sent free of charge to shareholders who so request and state their postal address or email address. This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail.

Number of shares and votes and information

The number of shares and votes in Oncopeptides amounts to 44,070,321 at the date of the issue of this notice. The shareholders are reminded of their right to require information in accordance with Chapter 7, Section 32 of the Swedish Companies Act.

Processing of personal data

For information about how personal data is processed, it is referred to the privacy notice available at Euroclear’s webpage https://www.euroclear.com/dam/ESw/Legal/privacy-notice-boss.pdf.